These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 32206560)

  • 1. Dynamic changes of acquired T790M mutation and small cell lung cancer transformation in a patient with EGFR-mutant adenocarcinoma after first- and third-generation EGFR-TKIs: a case report.
    Ma S; He Z; Fu H; Wang L; Wu X; Zhang Z; Wang Q
    Transl Lung Cancer Res; 2020 Feb; 9(1):139-143. PubMed ID: 32206560
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Small-Cell Carcinoma Transformation of Pulmonary Adenocarcinoma after Osimertinib Treatment: A Case Report.
    Taniguchi Y; Horiuchi H; Morikawa T; Usui K
    Case Rep Oncol; 2018; 11(2):323-329. PubMed ID: 29928211
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Heterogeneous resistance mechanisms in an EGFR exon 19-mutated non-small cell lung cancer patient treated with erlotinib: Persistent FGFR3-mutation, localized transformation to EGFR-mutated SCLC, and acquired T790M EGFR-mutation.
    Santoni-Rugiu E; Grauslund M; Melchior LC; Costa JC; Sørensen JB; Urbanska EM
    Lung Cancer; 2017 Nov; 113():14-17. PubMed ID: 29110841
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sequential small cell transformation and T790M mutation in an epidermal growth factor-mutant lung adenocarcinoma: A rare occurrence with significant management implications.
    Shastri M; Gupta P; Gupta N; Singh N; Bal A; Srinivasan R; Khosla D
    Cytopathology; 2022 Nov; 33(6):732-737. PubMed ID: 35867808
    [TBL] [Abstract][Full Text] [Related]  

  • 5. EGFR T790M mutation after chemotherapy for small cell lung cancer transformation of EGFR-positive non-small cell lung cancer.
    Sonoda T; Nishikawa S; Sakakibara R; Saiki M; Ariyasu R; Koyama J; Kitazono S; Yanagitani N; Horiike A; Ohyanagi F; Ninomiya H; Ishikawa Y; Nishio M
    Respir Med Case Rep; 2018; 24():19-21. PubMed ID: 29977749
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Successful treatment of EGFR T790M-mutant non-small cell lung cancer with almonertinib after osimertinib-induced interstitial lung disease: a case report and literature review.
    Wu L; Zhong W; Li A; Qiu Z; Xie R; Shi H; Lu S
    Ann Transl Med; 2021 Jun; 9(11):950. PubMed ID: 34350265
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Significant benefits of osimertinib in treating acquired resistance to first-generation EGFR-TKIs in lung squamous cell cancer: A case report.
    Zhang Y; Chen HM; Liu YM; Peng F; Yu M; Wang WY; Xu H; Wang YS; Lu Y
    World J Clin Cases; 2019 May; 7(10):1221-1229. PubMed ID: 31183356
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel ETV1 mutation in small cell lung cancer transformation resistant to EGFR tyrosine kinase inhibitors.
    Zhou Y; Bai H; Xia J; Xu WY; Cheng L; Xiong L
    Ann Transl Med; 2021 Jul; 9(14):1150. PubMed ID: 34430591
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An EGFR-mutant lung adenocarcinoma that transformed into small-cell lung cancer. A case report.
    Chowaniecova G; Berzinec P; Kosturiakova G; Plank L; Farkasova A; Sekeresova M; Juskanic D; Ondrus D
    Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2022 Dec; 166(4):451-454. PubMed ID: 36036563
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Primary resistance to osimertinib despite acquired
    Chang LK; Chang YL; Shih JY
    Respirol Case Rep; 2020 Mar; 8(2):e00532. PubMed ID: 32042433
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Newly emergent acquired EGFR exon 18 G724S mutation after resistance of a T790M specific EGFR inhibitor osimertinib in non-small-cell lung cancer: a case report.
    Zhang Y; He B; Zhou D; Li M; Hu C
    Onco Targets Ther; 2019; 12():51-56. PubMed ID: 30588029
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of osimertinib treatment on lung adenocarcinoma with squamous cell transformation harboring the T790M mutation: A case report and literature review.
    Yamaguchi F; Kato E; Wakabayashi A; Shikama Y
    Mol Clin Oncol; 2019 Aug; 11(2):127-131. PubMed ID: 31316771
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Small cell lung cancer transformation after EGFR-TKIs treatment in lung adenocarcinoma: A case report and literatures review.
    Chen X; Li D; Miao K; Shou T; Zhang W
    Medicine (Baltimore); 2023 Jan; 102(4):e32697. PubMed ID: 36705363
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Successful sequential treatment of refractory tumors caused by small cell carcinoma transformation and EGFR-T790M mutation diagnosed by repeated genetic testing in a patient with lung adenocarcinoma harboring epidermal growth factor receptor mutations: A case report.
    Nishioka N; Yamada T; Harita S; Hirai S; Katayama Y; Nakano T; Okura N; Tamiya N; Kaneko Y; Uchino J; Takayama K
    Respir Med Case Rep; 2018; 25():261-263. PubMed ID: 30310765
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sequential occurrence of T790M mutation and small cell lung cancer transformation in EGFR-positive lung adenocarcinoma: A case report.
    Hong E; Chen XE; Mao J; Zhou JJ; Chen L; Xu JY; Tao W
    World J Clin Cases; 2022 Mar; 10(9):2836-2843. PubMed ID: 35434119
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Resistance to epithelial growth factor receptor tyrosine kinase inhibitors in a patient with transformation from lung adenocarcinoma to small cell lung cancer: A case report.
    Fang L; He J; Xia J; Dong L; Zhang X; Chai Y; Li Y; Niu M; Hang T; Li S
    Oncol Lett; 2017 Jul; 14(1):593-598. PubMed ID: 28693210
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II trial of gefitinib plus pemetrexed after relapse using first-line gefitinib in patients with non-small cell lung cancer harboring EGFR gene mutations.
    Uchibori K; Satouchi M; Sueoka-Aragane N; Urata Y; Sato A; Imamura F; Inoue T; Tachihara M; Kobayashi K; Katakami N; Kokan C; Hirashima T; Iwanaga K; Mori M; Aoe K; Morita S; Negoro S
    Lung Cancer; 2018 Oct; 124():65-70. PubMed ID: 30268482
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A case of osimertinib-resistant lung adenocarcinoma responded effectively to alternating therapy.
    Hirakawa H; Komiya K; Nakashima C; Ogusu S; Nakamura T; Tanaka M; Takahashi K; Egashira Y; Kai K; Kimura S; Sueoka-Aragane N
    Ann Transl Med; 2018 Dec; 6(23):464. PubMed ID: 30603652
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A "triple whammy" in adenocarcinoma lung.
    Patro M; Gothi D; Vaidya S; Sah RB
    Lung India; 2019; 36(4):340-344. PubMed ID: 31290421
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Squamous cell transformation and
    Bruno R; Proietti A; Alì G; Puppo G; Ribechini A; Chella A; Fontanini G
    Oncol Lett; 2017 Nov; 14(5):5947-5951. PubMed ID: 29113230
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.